key: cord-0784440-xui25c83
authors: Batra, G.; Murugesan, D. R.; Das, S. J.; Chattopadhyay, S.; Mehdi, F.; Ayushi,; Gosain, M.; Singh, S.; Deshpande, S.; Bhattacharya, J.; Pandey, A. K.; Jha, S.; Goswami, S.; Das, A.; Dwivedi, T.; Sharma, N.; Kumar, S.; Sharma, P.; Kapoor, S.; Kshetrapal, P.; Wadhwa, N.; Thiruvengadam, R.; Kumar, R.; Gupta, R.; Garg, P. K.; Bhatnagar, S.; Research, DBT Consortium for COVID-19
title: Long-term Durable Humoral Immune Response to Heterologous Antigenic Exposure Post six months by Natural SARS-CoV-2 Infection and Vaccination
date: 2022-02-24
journal: nan
DOI: 10.1101/2022.02.23.22271381
sha: 8874321b2790b880dc1d6847153cfc83e65ae6c1
doc_id: 784440
cord_uid: xui25c83

Importance: Both vaccination and natural infection lead to immunity and may augment mutual immune response against SARS-CoV-2. There is a need for an evidence-driven booster vaccination policy depending on durability of immune response. Objective: To determine the durability of humoral immune response with varying age, vaccine type, duration, and previous natural infection at least six months after complete vaccination with ChAdOx1 nCov-19 or BBV152. Design: Cross-sectional observational study conducted between November 2021 and January 2022. Setting: Participants were drawn from a DBT COVID-19 Research Consortium cohort in Delhi National Capital Region, India. Participants: We included 2003 individuals who had completed six months after complete vaccination: (i) vaccination with ChAdOx1 nCoV-19 and aged 18-59 years, (ii) vaccination with ChAdOx1 nCoV-19 and aged [≥]60 years (iii) vaccination with BBV152 and aged 18-59 years (iv) vaccination with BBV152 and aged [≥]60 years (v) vaccination with either vaccine plus SARS-CoV-2 infection referred as those having hybrid immunity. A group of 94 unvaccinated individuals was also included for comparison. Exposure: Age, vaccination type, prior SARS-CoV-2 infection and duration from vaccination/infection. Main Outcome(s) and Measure(s): Humoral immune response determined by anti-RBD IgG concentrations and the presence of anti-nucleocapsid IgG. Results: The serum anti-RBD IgG antibodies were detected (cut-off 24 BAU/ml) in 85% participants with a median titer of 163 (IQR 73, 403) BAU/ml. In the hybrid immunity group, 97.6% [295 (IQR 128, 687) BAU/mL] tested positive for anti-RBD IgG compared to 81.3% [139 (IQR 62, 326) BAU/ml] of only vaccinated participants [{chi}2 test: p <0.001]. The median anti-RBD IgG titers were higher in the ChAdOx1 nCoV-19 versus BBV152 groups. The median anti-RBD IgG titer in the anti-nucleocapsid positive participants [326 (IQR 132, 739) BAU/ml] was significantly higher than in those without anti-nucleocapsid antibodies [131 (IQR 58, 288) BAU/ml; p <0.001]. The IgG anti-RBD antibodies was present in 85% of participants beyond a median of 8 months after complete vaccination. Conclusions and Relevance: Considering the wide seropositivity rates due to natural SARS-CoV-2 infection, recommendation for boosters should take into account past infections in the population

Vaccination is the most effective preventive strategy against SARS-CoV-2. Vaccines designed against the ancestral virus act primarily by inducing neutralizing antibodies (Nabs) against the receptor-binding domain (RBD) of viral spike (S) protein. Multiple waves of virus infection led by variants of concern (VoCs) such as alpha (B.1.1.17), delta (B.1.617.2), and omicron (B.1. 1.529) have led to breakthrough infections. Others and we have shown that antibody levels wane over time. [1] [2] [3] Antigenic exposure through both vaccination and natural infection may act synergistically to boost immune responses. 4 There is a need for an evidence-driven booster vaccination policy depending on durability of immune response. Vaccination against SARS-CoV-2 was started in January 2021 in India using an adenovirus vectored recombinant coronavirus vaccine, ChAdOx1 nCov-19 (Covishield, Serum Institute of India), and a whole virion inactivated SARS-CoV-2 vaccine, BBV152 (Covaxin, Bharat Biotech). We hypothesized that the durability of immune response would vary with age, vaccine type, duration, and previous natural infection. Hence, we studied the humoral immune responses in various groups of vaccinated individuals, with or without prior SARS-CoV-2 infection at least six months after complete vaccination.

The participants were sampled cross-sectionally from an ongoing DBT COVID-19 Research Consortium cohort between November 2021 and January 2022 (Appendix). We included five groups of individuals who had completed six months after complete vaccination: (i) vaccination with ChAdOx1 nCoV-19 and aged 18-59 years, (ii) vaccination with ChAdOx1 nCoV-19 and aged ≥ 60 years (iii) vaccination with BBV152 and aged 18-59 years (iv) vaccination with BBV152 and aged ≥ 60 years (v) vaccination with either vaccine plus prior SARS-CoV-2 infection referred as those having hybrid immunity. A group of unvaccinated individuals was also included for comparison. Written informed consent was obtained from the study participants.

Institute ethics committees approved the study.

The study participants were interviewed for details on SARS-CoV-2 vaccination including the type, number of doses, and date of vaccination, profession, comorbidities and prior SARS-CoV-2 infection. The dates of vaccination were verified by the certificate issued by Government of India. Five percent of interviews were monitored for quality control.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 24, 2022. ;

Anti-RBD IgG concentrations in the plasma samples were determined by enzyme-linked immunosorbent assay (ELISA) as described earlier with minor modifications and are reported as BAU/mL. 5 In addition, anti-nucleocapsid antibodies were detected using a qualitative ELISA.

We estimated a sample size of at least 296 participants for each group to detect a decline of anti-IgG RBD by 30% after 6 months of vaccination with 80% power and at 5% significance after adjusting for multiple comparisons. The baseline characteristics are given as median (interquartile range) or number (percentage) as appropriate. The differences in ELISA titers between different groups were compared using unpaired Student's t-test after log2 transformation. Categorical parameters were compared by chi-square test. All statistical analysis was done using R 4.1.1. A p-value of <0.05 was considered statistically significant.

We Table 1 . (Table S1 ).

In summary, we have shown the durability of IgG anti-RBD antibodies in 85% of participants beyond a median of 8 months after complete vaccination. The antibody concentrations were significantly higher in those with hybrid immunity.

Humoral immune responses to mRNA vaccines are known to wane over a period of time, particularly after 5 months, more so in individuals older than 60 years of age. 6,7 But these may not be generalizable to other vaccine types and in different geographic regions in the context of immunity provided by natural infection. In the present study, we found higher positivity and higher levels of antibodies among those with hybrid immunity. In the vaccinated group, it is probable that many participants had prior asymptomatic infection consistent with a high seroprevalence of natural infection in the population. 8, 9 We found 15% ChAdOx1-nCoV-19 only participants positive for anti-nucleocapsid antibody suggesting previous infection. However, in the vaccination plus infection group, nearly two-thirds of participants were negative for antinucleocapsid antibody possibly suggesting faster waning of anti-nucleocapsid than anti-RBD antibodies. 10 If we extrapolate this finding to vaccine alone groups, 45% ChAdOxnCoV-19 group might have had asymptomatic natural infection and a similar percentage in the BBV-152 vaccine given the almost similar vaccine effectiveness of these 2 vaccines. 11, 12 This inference is important because most countries have been affected by a minimum of three waves of different SARS-CoV-2 VoCs, most recent being omicron, infecting a large proportion of population. Such a natural infection should be equivalent to at least another dose of vaccine, reinforcing the protection provided by vaccination alone. It is likely that other modes of protection such as cellular responses provided by natural infection are better than those induced by vaccines. Clinically, naturally infected people have shown to be better protected than vaccination alone. 13 Current data suggest that vaccination plus natural infection provides even better protection. 14,15 Therefore, recommendation for boosters should take into account past infections in the population.

The strengths of our study include inclusion of inactivated vaccine about which sparse data are available, adequate sample size, inclusion of different age groups and profiling antinucleocapsid antibody positivity for unidentified past infections. Our study has a few limitations, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271381 doi: medRxiv preprint inability to unequivocally identify individuals with prior infection, and a small sample size of unvaccinated group, a reflection of >90% of eligible population having been vaccinated in India as in many other countries.

Our data may guide policy for a booster dose. Considering the wide seropositivity rates due to natural infection, the priority for a booster should be for vulnerable and high-risk groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. None of the authors were paid by any pharmaceutical company or any other agency to write this article. All authors had full access to the full data in the study and accept responsibility to submit for publication.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271381 doi: medRxiv preprint 

Duration between two doses (days)* # A frontline worker was defined as one engaged in the delivery of essential services such as health care providers, police, and municipal workers . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; * Sensitivity analysis was done in the uninfected ChAdOx1 nCoV-19 groups after exclusion of the participants whose anti-Nucleocapsid antibodies were positive (Table S2) # anti-RBD IgG antibodies were positive by qualitative assay in one-fourth (72 of 300) of participants who were reported negative on the quantitative assay.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271381 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271381 doi: medRxiv preprint Figure S1 : Distribution of study participants among different groups *The groups were combined into a group of "vaccinated plus infected individuals" . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 24, 2022. ; *median (Interquartile range) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271381 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 24, 2022. ; https://doi.org/10.1101/2022.02.23.22271381 doi: medRxiv preprint

Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study

Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants

Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India

Aiims WUS study team of. Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers

The authors gratefully acknowledge the DBT Consortium for COVID-19 Research for enabling this study. We sincerely thank participants of the study for providing the blood samples. 

We declare that we have no conflicts of interest.

The deidentified dataset and related codes for analysis may be available to researchers upon request addressed to the corresponding author after publication after the approval of the Department of Biotechnology, Government of India.